RankingsPricing
  1. US-listed companies
  2. NEUROCRINE BIOSCIENCES INC
  3. Raw

NEUROCRINE BIOSCIENCES INCNBIX

Market cap
$15.2B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Cash and cash equivalents506445317483255142112187341263251233
Available-for-sale debt securities-------509---726781843
Accounts receivable------3156127157186350-479
Inventory-------11172831353857
Other current assets1234538201730467998112
Total current assets1321891481983843105557388311,0169731,4541,6071,725
Deferred tax assets---------319315306363486
Available-for-sale debt securities-------216----688740
Right-of-use assets--------74839787277509
Equity investments------------162125
Property and equipment, net2223361134424559597183
Intangible assets, net-----------373637
Other noncurrent assets---------34255016
Total assets1381961552434753658189931,3061,7352,0732,3693,2513,719
Accounts payable and accrued liabilities------5486141169226348449462
Convertible senior notes--------409--169170-
Other current liabilities------02151820213646
Total current liabilities4716121626305488565187246538655508
Noncurrent operating lease liabilities--------879410594258455
Other noncurrent liabilities000000--17101230106166
Total liabilities7842343450504455126696096996611,0191,129
Preferred Stock, Value, Issued--------------
Common Stock, Value, Issued00000000000000
Additional paid-in capital----1,3411,3711,5731,6601,7681,8502,0112,1222,3822,555
Accumulated other comprehensive income-0-00-0-1-0-2-212-2-876
Retained earnings (accumulated deficit)-725-720-766-826-915-1,056-1,199-1,178-1,133-725-636-407-15729
Total stockholders’ equity601541202094243153724816371,1261,3741,7082,2322,590
Total liabilities and stockholders’ equity1381961552434753658189931,3061,7352,0732,3693,2513,719